Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologist-oncologists, medical oncologists, oncology nurses, NPs, PAs, and other HCPs involved in the treatment and management of MF, PV, and ET.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Analyze the latest data on current and emerging therapies for MF, PV, and ET
- Create an evidence-based treatment plan for a patient with MF, PV or ET that balances patient-, disease-, and treatment-related considerations
- Apply best practices for identifying and managing the AEs associated with treatment for MF, PV, and ET
- Implement supportive care approaches to address symptom burden in patients with MF, PV or ET
Rami Komrokji, MD
Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Tampa, FL
Disclosures: Advisory Board: AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Pharma Essentials, Rigel; Consultant: Genentech, Geron; Grant/Research Support: Bristol Myers Squibb; Shareholder: Jazz Pharmaceuticals, PharmaEssentia, Rigel.
Gabriela Hobbs, MD
Assistant Professor
Harvard Medical School
Clinical Director, Leukemia Service
Massachusetts General Hospital
Cambridge, MA
Disclosures: Advisor: Bristol Myers Squibb, GSK, Incyte, Novartis, Pfizer, Sobi; Consultant: Cogent, Merck, PharmaEssentia; Grant/Research Support: Incyte.
John Mascarenhas, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Director, Center of Excellence in Blood Cancers and Myeloid Disorders
Director, Adult Leukemia Program Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
New York, NY
Disclosures: Consultant; AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Disc, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Keros, Merck, Novartis, Pfizer, PharmaEssentia, Roche, Sumitomo; Grant/Research Support; AbbVie, AJAX, Bristol Myers Squibb, CTI/SOBI, Geron, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia.
Naveen Pemmaraju, MD
Professor, Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Executive Director, MDACC Cancer Network for Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, JNJ, Karyopharm, Menarini-Stemline Group, Morphosys, Pacylex, Protagonist; Board of Directors/Management: Dan's House of Hope; Consultant: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, JNJ, Karyopharm, Menarini-Stemline Group, Morphosys, Pacylex, Protagonist; Grant/Research Support: Sager Strong Foundation, United States Department of Defense (DOD); Speakers’ Bureau: AbbVie, Bristol Myers Squibb Consulting, CTI BioPharma, GSK Consulting, Immunogen, Incyte, JNJ, Karyopharm, Menarini-Stemline Group, Morphosys, Pacylex, Protagonist.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Geron, Incyte Corporation, and PharmaEssentia.
Physicians’ Education Resource® is proud to partner with the International Academy for Clinical Hematology
